At the 2026 iMPSS Asia-Pacific Summit and the 9th Organoid and Organ-on-a-Chip Academic Conference, researchers demonstrated AI-integrated organ-on-a-chip technology. Experts said the combination of AI with organoids and organ-on-a-chip will create a humanized, data-driven drug development model. Zhang Yujian, CEO of Suzhou Beilun Bio, presented the progress of the world's first personalized mRNA tumor vaccine clinical study integrating organ-on-a-chip and AI.